Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein turnover in women

被引:10
|
作者
Toth, Michael J.
Sites, Cynthia K.
Matthews, Dwight E.
Casson, Peter R.
机构
[1] Univ Vermont, Hlth Sci Res Facil 126B, Dept Med, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2006年 / 291卷 / 03期
关键词
estrogen; menopause; fat-free mass; sarcopenia; progesterone;
D O I
10.1152/ajpendo.00600.2005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The age-related decline in fat-free mass is accelerated in women after menopause. The role of ovarian hormone deficiency in the regulation of fat-free mass, however, has not been clearly defined. To address this question, we examined the effect of ovarian hormone suppression on whole body protein metabolism. Whole body protein breakdown, oxidation, and synthesis were measured using [C-13] leucine in young, healthy women with regular menstrual patterns before and after 2 mo of treatment with gonadotropin-releasing hormone agonist (GnRHa; n = 6) or placebo (n = 7). Protein metabolism was measured under postabsorptive and euglycemic-hyperinsulinemic-hyperaminoacidemic conditions. Ovarian suppression did not alter whole body or regional fat-free mass or adiposity. In the postabsorptive state, GnRHa administration was associated with reductions in protein breakdown and synthesis (P < 0.05), whereas no change in protein oxidation was noted. Under euglycemic-hyperinsulinemic-hyperaminoacidemic conditions, a similar reduction (P < 0.05) in protein synthesis and breakdown was noted, whereas, protein oxidation increased (P < 0.05) in the placebo group. Testosterone, steroid hormone precursors, insulin-like growth factor I, and their respective binding proteins were not altered by GnRHa administration, and changes in these hormones over time were not associated with GnRHa-induced alterations in protein metabolism, suggesting that changes in protein turnover are not due to an effect of ovarian suppression on other endocrine systems. Our findings provide evidence that endogenous ovarian hormones participate in the regulation of protein turnover in women.
引用
收藏
页码:E483 / E490
页数:8
相关论文
共 50 条
  • [1] Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal
    Cooper, Brian C.
    Sites, Cynthia K.
    Casson, Peter R.
    Toth, Michael J.
    FERTILITY AND STERILITY, 2007, 87 (05) : 1131 - 1138
  • [2] Induction of circulating monocyte chemoattractant protein-1 in women with gonadotropin-releasing hormone agonist
    Matsui, Sumika
    Yasui, Toshiyuki
    Uemura, Hirokazu
    Yamamoto, Satoshi
    Matsuzaki, Toshiya
    Tsuchiya, Naoko
    Yuzurihara, Mitsutoshi
    Kase, Yoshio
    Irahara, Minoru
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2011, 90 (02) : 227 - 234
  • [3] The effects of gonadotropin-releasing hormone agonist (buserelin) and orchidectomy on bone turnover markers and histomorphometry in rats
    Mohamad, Nur-Vaizura
    Ima-Nirwana, Soelaiman
    Chin, Kok-Yong
    AGING MALE, 2020, 23 (05) : 327 - 334
  • [4] Gonadotropin-releasing hormone antagonists in controlled ovarian stimulation
    Diedrich, Klaus
    Felberbaum, Ricardo
    Al-Hasani, Safaa
    GYNAKOLOGE, 2020, 53 (08): : 517 - 521
  • [5] Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice
    Romero, Iris L.
    Gordon, Ilyssa O.
    Jagadeeswaran, Sujatha
    Mui, Keeley L.
    Lee, Woo Seok
    Dinulescu, Daniela M.
    Krausz, Thomas N.
    Kim, Helen H.
    Gilliam, Melissa L.
    Lengyel, Ernst
    CANCER PREVENTION RESEARCH, 2009, 2 (09) : 792 - 799
  • [6] The Protective Effects of Gonadotropin-releasing Hormone Agonist on Ovarian Functions in Breast Cancer Patients Receiving Chemotherapy
    Wang, Chen
    Yu, Xing-Fei
    DISCOVERY MEDICINE, 2018, 25 (135) : 7 - 11
  • [7] Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation
    Han, Ruxue
    Song, Ziyi
    Li, Huiling
    Wang, Chaohua
    Zhang, Leping
    Yang, Xin
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone
    Gavin, Kathleen M.
    Shea, Karen L.
    Gibbons, Ellie
    Wolfe, Pamela
    Schwartz, Robert S.
    Wierman, Margaret E.
    Kohrt, Wendy M.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2018, 315 (02): : E316 - E325
  • [9] A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage
    Park, Ilhae
    Lee, Sanghoon
    Ryu, Ki-Jin
    Min, Kyung-Jin
    Hong, Jin Hwa
    Song, Jae Yun
    Lee, Jae Kwan
    Lee, Nak Woo
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (06) : 783 - 789
  • [10] Chronic treatment with an agonist of gonadotropin-releasing hormone enhances luteal function in cattle
    Davis, TL
    Mussard, ML
    Jimenez-Severiano, H
    Enright, WJ
    Kinder, JE
    BIOLOGY OF REPRODUCTION, 2003, 69 (02) : 398 - 403